Figure 3.

PI3K and Akt activation by CCR9-CCL25 interactions. MDA-MB-231 cells were tested for their ability to activate PI3K and Akt following treatment with CCL25, cisplatin and specific kinase inhibitors (wortmannin and PF-573, 228). In situ total and active (phosphorylated) PI3K and Akt levels were quantified by Fast Activated Cell-based ELISA (FACE) assay before (0 minutes) or after (5 or 10 minutes) CCL25 stimulation in the presence of cisplatin and kinase inhibitors.

Johnson-Holiday et al. World Journal of Surgical Oncology 2011 9:46   doi:10.1186/1477-7819-9-46
Download authors' original image